![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1800B Healthcare Enterprise Group PLC 26 July 2004 Healthcare Enterprise Group plc Ebiox surface cleaning product passes tests required for US Environment Protection Agency approval Healthcare Enterprise Group PLC ("HCEG"), the healthcare products and services company, announces that its Trionic Plus product from the Ebiox family of products has passed tests required for US Environment Protection Agency (EPA). EPA approval will allow the product to be offered to US hospitals and related facilities and for industrial antimicrobial and other cleaning uses in the US. Trionic Plus is a high power "terminal" disinfectant proven to be effective at combating MRSA and other pathogens. HCEG believes that the product offers significant safety advantages over all other commonly used disinfectants and does not contain alcohol, chlorine or other irritating vapours. Trionic Plus contains soil lifting agents and biocides, which allow removal of soils and microbes down to the molecular level. It removes the invisible surface biofilms, which are believed to provide a rich breeding ground for the development of resistant bacteria. For high-risk contaminated areas Trionic Plus provides a fast-kill solution for bacteria on hygienic surfaces such as floors, walls, tables, beds and public access areas. Unlike other commonly used surface cleaners, Trionic Plus works by oxidation rather than toxification. This means that there is no need to rotate disinfectants because there is no chance of bacterial resistance developing. HCEG is considering a range of US marketing and distribution options for Trionic Plus, together with similar strategies for its surgical instrument cleaner range, which received EPA approval in March. Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented: "The US represents over half of the world's healthcare economy, with an annual expenditure in excess of US$1.7 trillion and is a market with which we are familiar. The sheer size of the market means entry into the US represents an exciting opportunity for the Ebiox product range. Since the US tends to lead in the adoption of new healthcare technologies, we are confident that the obvious benefits these products have over existing alcohol or bleach disinfectants will result in active product investigation and assessment by US hospitals and other healthcare facilities." 26 July 2004 Enquiries: Healthcare Enterprise Group 020 7351 7500 Stuart Bruck Executive Chairman Gordon Wood Group Chief Operating Officer College Hill 020 7457 2020 Nicholas Nelson Corinna Dorward Note to editors Ebiox Ebiox produces a range of patented cleansing, decontamination and disinfectant products. The range includes hand hygiene products, hard surface cleaners, disinfectants and products to clean and decontaminate surgical instruments. Ebiox antibacterial handwash and handrub are proven effective against MRSA, E-coli and other important pathogens and are fully compliant with EU standards. Uniquely, the products do not use alcohol, which has a drying effect and can be a skin irritant. The hard surface cleaners, particularly the Trionic Plus trigger spray and Azowipe Active wipes are based on a lifting and removing concept, completely removing biofilms and cleaning to molecular level. The product continues to be active after use and cleans through oxidation action, not toxification which means that there is no need to rotate disinfectants because there is no chance of resistance developing (cf GMP guidelines). Ebiox also offers a range of products for the effective cleaning of re-usable instruments. Critically, these products remove all debris prior to the sterilisation process thereby ensuring complete decontamination. They have proven to be more effective than natural detergents and enzymatic detergents currently available. As well as the current range of products, Ebiox also has products for the decontamination of dental aspiration lines and a veterinary product range, EbioxVET. Healthcare Enterprise Group PLC HCEG is quoted on the UK AIM stock market with its head office in London and subsidiary offices in Manchester, Liverpool, Cheshire, Germany and the USA. HCEG is a business engaged in medical product distribution, occupational health, first aid and medical consultancy markets. These businesses underpin a range of innovative medical devices, which will be introduced to the market via HCEG's own distribution network on an international basis. HCEG owns 51% of the shares in Ebiox Ltd, a management contract for the business and options to acquire up to 100% of Ebiox Ltd. This information is provided by RNS The company news service from the London Stock Exchange END MSCQKNKQPBKDQOB
1 Year Healthcare Enterprise Chart |
1 Month Healthcare Enterprise Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions